卫宁健康(300253) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 494,492,405.71, representing a 10.09% increase compared to CNY 449,172,857.10 in the same period last year[9] - Net profit attributable to shareholders was CNY 16,620,407.26, a significant turnaround from a loss of CNY 63,534,739.90, marking a 126.16% increase[9] - The net profit after deducting non-recurring gains and losses was CNY 8,687,732.19, improving by 111.74% from a loss of CNY 74,028,076.85 in the previous year[9] - Basic earnings per share increased to CNY 0.0077 from a loss of CNY 0.0296, reflecting a 126.01% improvement[9] - The company achieved operating revenue of 494.49 million yuan, a year-on-year increase of 10.09%[45] - Net profit attributable to shareholders reached 16.62 million yuan, up 126.16% year-on-year[45] - The core business of healthcare information technology generated revenue accounting for 89.87% of total revenue, with a year-on-year growth of 16.81%[45] - The total comprehensive income for the current period is 6,494,450.04, compared to -90,204,109.26 in the previous period[60] Cash Flow and Assets - The company's cash flow from operating activities showed a net outflow of CNY 108,888,969.06, worsening by 18.32% compared to CNY 92,026,081.61 in the same period last year[9] - As of March 31, 2024, the company's cash and cash equivalents amounted to CNY 973.09 million, down from CNY 1.114 billion at the beginning of the period[28] - The total current assets as of March 31, 2024, were CNY 4.746 billion, slightly down from CNY 4.854 billion at the beginning of the period[28] - The total cash and cash equivalents at the end of the period is 904,104,252.84, down from 990,968,902.14 in the previous period[62] Liabilities and Equity - The total liabilities decreased to CNY 2,716,898,318.12 from CNY 2,867,668,499.40, reflecting a reduction of about 5.3%[52] - The total equity attributable to shareholders increased to CNY 5,761,421,811.75 from CNY 5,687,089,041.72, an increase of approximately 1.3%[52] Shareholder Information - The number of shareholders at the end of the reporting period was 77,341, with the largest shareholder holding 8.17% of the shares[17] - The company’s total shares held by the top 10 shareholders accounted for 19.63% of the total share capital[39] - The total number of restricted shares at the end of the period was 298,767,886 shares[44] Operational Efficiency - The company recorded a 37.56% decrease in selling expenses, primarily due to reduced personnel costs during the reporting period[14] - Non-operating income decreased by 99.49%, mainly due to a reduction in income not directly related to regular business activities[14] - The company experienced a significant reduction in credit impairment losses and asset impairment losses, decreasing by over 200% due to increased cash collections[37] Investment and Projects - The company utilized CNY 14.1372 million of the raised funds for the "WiNEX MY project," with a cumulative usage of CNY 151.5781 million, achieving a usage progress of 79.08%[25] - The company confirmed government subsidies totaling CNY 26.1561 million, accounting for approximately 7.31% of the audited net profit attributable to shareholders for 2023[27] Revenue Breakdown - Revenue from software sales and technical services accounted for 72.04% of total revenue, growing by 14.89% year-on-year[45] - Revenue from hardware sales represented 17.83% of total revenue, with a year-on-year increase of 25.24%[45] - Internet healthcare revenue accounted for 10.13% of total revenue, showing a decline of 27.10% year-on-year[45] Share Issuance and Corporate Governance - The company issued 6,614,595 new shares as part of its stock option incentive plan during the reporting period[27] - The company completed the election of the sixth board of directors and supervisory board on March 21, 2024[25]